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Introduction 
Chronic pulmonary insufficiency is the most common morbidity of extremely preterm birth. It is 
associated with increased resource utilization during the initial hospitalization, as well as short and 
longer-term respiratory morbidities that drive health care costs and are associated with worse 
neurodevelopmental outcomes (1).  
Chronic pulmonary insufficiency of prematurity (CPIP) refers to respiratory morbidity after 
preterm birth during the birth hospitalization and through infancy and childhood (Figure 1). It is usually 
captured during the initial hospitalization using a diagnosis of bronchopulmonary dysplasia (BPD). 
Despite advances in respiratory management, the incidence of BPD in the smallest neonates continues to 
rise, (2) and there have been few therapeutic advances over the last 25 years (3). There are many reasons 
for these ongoing gaps in drug development including difficulties with clinical trial design, a population 
that is viewed as high risk by regulators and industry, and the need to wait months or even years to 
establish safety and efficacy. These problems are compounded by definitions of BPD that are applied 
inconsistently and are not clearly related to long-term outcomes of importance to clinicians and families.  
Consideration of CPIP is important because the diagnosis of BPD does not capture all infants 
with chronic pulmonary insufficiency. The concept of BPD grew out of radiological and pathological 
examinations of neonates with significant lung injury, and assumes that an oxygen requirement stems 
from lung damage that is similar between infants, and that different lung insults produce similar effects on 
the lung. While oxygen dependence is related to injury of the lung parenchyma, it may also be influenced 
by injury or immaturity of the brain, airways, or pulmonary vasculature. Moreover, an early measure of 
gas exchange may not reflect the pathophysiology of later problems such as reactive airways disease or 
susceptibility to viral infections. Optimizing and harmonizing clinical definitions of CPIP, including BPD 
and later respiratory outcomes, while developing strong surrogate endpoints useful for regulators, industry, 
clinicians and families would greatly benefit future interventional trials and accelerate the development of 
new therapies for these high risk and vulnerable patients. 
Page 3 
 
 
Current Endpoints: Benefits and Limitations for Drug Development 
The definition of BPD has evolved substantially over the past 50 years in conjunction with 
improved survival for extremely low birth weight (ELBW) infants (Table 1). While CPIP exists on a 
continuum of disease severity over time, BPD is defined as a dichotomous (yes/no) outcome of 
requirement for supplemental O2 at an arbitrary 36 week PMA time point. There is not consensus that 
BPD predicts chronic pulmonary insufficiency or represents the most appropriate definition for clinical 
trials of drug development (4). A recent systematic review found that many clinical trials did not use a 
discrete BPD definition (5), a situation complicated by the absence of biomarkers or imaging techniques 
to characterize or predict BPD.  
An additional challenge is that criteria for O2 use for treatment of upper airway disease or 
immaturity of respiratory control (e.g. apnea and feeding difficulties) vary between centers and clinicians. 
For example, in the multicenter Prematurity and Respiratory Outcomes Program (PROP) study, 47% of 
765 surviving ELBW infants remained on nasal cannula support at 36 weeks PMA, but with substantial 
variation in the flow and/or O2 concentrations used (6). Although an infant receiving 21% O2 delivered at 
4 liters/minute (LPM) by high flow nasal cannula would be classified as 'no BPD' by the Shennan 
definition, it is not known whether there is less intrinsic lung disease and better long term outcomes than 
an infant receiving 0.1 LPM of 100% O2 and classified as ‘severe BPD’.  
BPD is a functional description that is not correlated to specific mechanisms but has become 
shorthand for CPIP in general. A functional description may be useful in clinical trials as a way to capture 
multiple influences. However, the current 36-week PMA definition of BPD remains an imperfect 
surrogate to predict chronic pulmonary morbidity in infancy, later childhood and adolescence. For 
instance, some interventions such as vitamin A significantly reduced the incidence of BPD at 36 weeks 
PMA, but did not affect long-term respiratory morbidity (7, 8). Other interventions such as high 
frequency oscillatory ventilation, superoxide dismutase and late surfactant failed to reduce BPD, but 
improved longer-term respiratory outcomes (9-11). These discrepancies may reflect the range of tissues 
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that can be injured in premature babies: Vitamin A may support more efficient gas exchange in the short 
term but have no effect on airways, while other interventions may have their dominant effects on airways 
or other tissues. BPD may still be a useful as a functional clinical outcome that captures lung function at 
the time a preterm infant should transition out of the hospital, in the way that functional outcomes such as 
FEV1 are useful in conditions such as cystic fibrosis.  
Goals of definitions: Perspectives of Clinicians, Industry, Regulators and Parents 
How should respiratory disease of prematurity be optimally defined for the purposes of drug 
development? Ideally, a definition would be clinically meaningful and strongly associated with the 
subsequent development of long-term respiratory morbidities. The definition should be objective, 
standardized, and incorporate unambiguous, specific guidance about how to factor in the use of O2 and 
non-invasive respiratory support. As other morbidities of prematurity (eg, necrotizing enterocolitis, 
retinopathy of prematurity, intraventricular hemorrhage) are measured on a scale, a validated "BPD 
severity scale" ranging from no morbidity (no O2, respiratory support, or medications) to severe morbidity 
would be useful. Definitions should use components that are easily extractable from the health record, and 
allow for the reliable evaluation of infants transferred to another hospital or discharged before the optimal 
time of BPD assessment, since these infants are often not appropriately classified (6, 12). Definitions 
should also incorporate infants that die of progressive lung injury between 7 days of life and 36 weeks 
PMA, as these infants may gain the most from early/prophylactic treatment approaches.  
From the perspective of the pharmaceutical industry, a simple and pragmatic definition will 
encourage its introduction into routine neonatal clinical practice in all hospitals, not just at university and 
research based institutions. Regulatory authorities need to assess whether endpoints other than survival 
measure a meaningful aspect of how a patient feels or functions in daily life. Endpoints should display 
good inter- and intra-observer agreement and stability over time in individual babies; and have a 
predictable relationship to mechanisms that are amenable to drug therapy, which will facilitate dose 
selection and the development of biomarkers. 
Industry, trialists, and regulators also need to consider the perspective of parents on what 
constitutes meaningful outcomes. Composite outcomes such as "death or BPD" can be difficult for 
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parents to understand, as families do not view these competing outcomes as equivalent (13). Moreover, if 
an infant survives, a requirement for a nasal cannula at 36 weeks PMA has a very different impact 
compared to home oxygen or ventilation. Moving beyond the dichotomous BPD outcome to include the 
long-term consequences of lung injury will measure outcomes that are important to this group.  
Proposed endpoints for clinical trials that investigate CPIP  
36 week PMA definition of BPD: When compared to term infants, ELBW infants are at higher 
risk for pulmonary morbidity. Premature infants with BPD have longer initial hospitalizations, increased 
rates of death and long-term disability, use of respiratory medications, and abnormal pulmonary function 
during childhood (14). However, other studies have failed to demonstrate significant differences in long-
term pulmonary outcomes for infants with and without BPD at 36 weeks PMA (14-16), leading regulators 
to increasingly view the 36-week endpoint as inadequate for drug approval.   
Restricting the diagnosis of BPD to a dichotomous outcome limits information about the disease 
itself. The definition of BPD at 36 weeks PMA should be expanded to a continuous outcome that 
incorporates all methods of non-invasive respiratory support and use of respiratory medications (diuretics, 
bronchodilators, corticosteroids) that can influence the need for supplemental O2. We propose 
incorporating a simple respiratory checklist administered at 36 weeks PMA or discharge into the health 
records of all preterm babies, to allow development of an objective BPD scoring system, particularly for 
those infants transferred to another hospital or discharged home (Table 2). Endpoints at 36 weeks PMA 
should also incorporate pulmonary hypertension screening for infants with moderate to severe BPD, 
which is found in 10-15% of this population and associated with higher mortality and morbidity (17-19). 
Finally, the 36-week PMA determination is typically made on a single day during the 36th postmenstrual 
week, despite changing needs for supplemental O2 because of immaturity in control of breathing, feeding 
patterns, and airway protection inherent to this time period. This variability in timing likely contributes to 
the poor long-term predictive value of a 36 weeks PMA diagnosis. We recommend extending the 
assessment of oxygen dependency to maintain the oxygen saturation in the normal range (90-95%), and to 
include at least 3 consecutive days of the 36th postmenstrual week.  
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 40 weeks PMA: As immature respiratory control and feeding difficulties often resolve by term 
equivalent, targeting a 40 week PMA endpoint may improve upon the pitfalls of the 36 week endpoint 
and better identify those infants with persistent airway and/or parenchymal disease. Although some 
infants will already be discharged, the PROP cohort found that 41% of survivors (315/765) were still in 
the hospital at 40 weeks PMA (6). A child could be imputed as “No BPD” at 40 weeks PMA or the time 
of discharge if off all respiratory support (including non-invasive methods) for a period of time (e.g. 7 
days). The result would be an alternative definition at 40 weeks PMA or discharge that is dichotomous 
(NO BPD if in RA with no support, YES BPD if receiving any form of support) but also continuous by 
assigning a score based on levels of respiratory support. A numeric scale that incorporates inspired O2 
concentration, flow rate and medication use would have the advantage of being a statistically more 
powerful outcome than a simple dichotomous outcome. For instance, data from the Canadian Neonatal 
Network show that a combined outcome of O2 or respiratory support (oxygen, CPAP, or ventilator use) at 
40 weeks PMA was a superior predictor of serious respiratory morbidity at 18-21 months corrected 
gestational age (CGA) (20). However, this time point must still be validated in multiple international 
cohorts.  
1 year CGA: Premature infants more frequently have pulmonary morbidity at school age and 
beyond, including asthma, repeated pulmonary infections, exercise intolerance, and lung function 
abnormalities (14, 16). These are important outcomes, but impractical endpoints for most neonatal 
interventional trials. In addition, these long-term respiratory morbidities may occur regardless of the 
development of BPD, suggesting that mechanisms for longer-term pulmonary morbidity may differ from 
those causing O2 dependency at 36 weeks PMA (21). One small study suggested that pulmonary function 
testing at one year CGA predicted respiratory symptoms at five years of age while a diagnosis of BPD at 
36 weeks did not (22). Unfortunately, lung function assessments at one year CGA use complex equipment 
not available at most centers and sedation of the infant, leading most parents to refuse consent (23).  
Outcomes such as the need for re-hospitalization, home O2 therapy, and frequent visits to a health 
care provider or the emergency department in the first years of life have not been systematically reported 
in most studies, although this is beginning to change (24, 25). The use of respiratory medications (e.g. 
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bronchodilators, inhaled/systemic steroids, leukotriene inhibitors) to treat respiratory symptoms or 
illnesses during the first year of life also suggests the presence of chronic respiratory morbidity, but is 
limited by the absence of evidence of efficacy, clear standards for treatment, and marked center-to-center 
variability.  
At one year CGA, a four-week respiratory diary card completed by parents captured the extent of 
coughing, wheezing and respiratory medications use and was highly predictive of two-year respiratory 
outcomes (15). This study did not find that re-hospitalization was a significant predictor of longer-term 
respiratory dysfunction. However, the total number and duration of hospital re-admissions was related to 
the severity of BPD and is a clinically meaningful outcome for families. The biggest problem with using a 
primary one year outcome measure is the impact of confounding variables such as environmental factors 
such as smoking in the home, medication compliance (including any immunoprophylaxis), and 
respiratory syncytial virus (RSV) and other viral infections. Furthermore, while rates of follow-up are 
97% in the UK and Australia, improved rates of follow-up in other countries such as the US would need 
to be achieved. 
Other Outcome Considerations  
Premature infants who have continuing pulmonary insufficiency at the time of hospital discharge 
present a significant challenge for the parents, family, and primary care providers. Common problems for 
these infants are marginal nipple feeding; the need for partial or complete gavage feeding; fussiness, 
irritability and inconsolability; and the need for multiple medications and medical visits. Outcomes such 
as growth, sleep patterns, behavioral and neurodevelopmental issues, and parental stress are also very 
important (13). An objective Quality of Life (QOL) scale is needed for this age group to obtain input from 
the parent as well as timely observations regarding their infant. The PedsQLTM Pediatric Quality of Life 
Inventory Infant Scales is one such instrument for children ages 2-12 years of age 
(www.pedsql.org/index.html). There would be a role for developing smart mobile tools to provide an 
easily accessible portal for parents to fill out serial QOL assessments.  
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Identification of Severe or Early Lethal CPIP 
The population of ELBW infants most in need of innovative therapies may be those who die of 
"early, lethal BPD" before a diagnosis of BPD can be formally made. The cause of death for these infants 
is often imprecisely assigned. When the NICHD Neonatal Research Network (NRN) examined deaths 
over 19 years, infants died of “RDS” well past the first week of life, and died of "BPD" prior to 36 weeks 
PMA.(26) In the recent PROP cohort, 63/835 ELBW infants died prior to 36 weeks PMA (6).  Of the 35 
infants who died after two weeks of age, 25 (71%) were retrospectively adjudicated to have had chronic 
respiratory failure as a primary cause of death.  Chronicity was arbitrarily assessed by the respiratory 
status within seven days of death, with many of these infants having been assigned other causes of death. 
Thus, about 3% of the entire cohort had "early lethal BPD".   
Clinical trials often report the combined outcome of death or BPD because death prior to 36 
weeks PMA is a competing adverse outcome. However, neither epidemiologic nor trial reports 
independently identify deaths due to severe respiratory failure prior to 36 weeks PMA. These deaths are 
often associated with elements of a BPD phenotype, and some of these deaths may be due to 
complications (e.g. sepsis) that may have occurred secondary to the care needed to support the respiratory 
failure, such as the prolonged need for vascular access and respiratory support, nutritional deficits and 
prolonged antibiotic exposure.  
 The concept of severe CPIP or BPD should also evolve to better capture those infants who 
survive to 36 or 40 weeks PMA and have severe respiratory failure needing aggressive treatment. There is 
a need for valid predictors for the severe form of CPIP that can be applied soon after birth and within the 
first several weeks of life, as these infants should be specifically targeted for trials of innovative 
therapies. A modified NICHD BPD Calculator may be a good option for such a predictive instrument (27). 
For example, continued need for mechanical ventilation at day seven is a strong indicator for increased 
BPD risk, yet this likely indicates a need for even earlier predictors (e.g., antenatal factors, need for 
resuscitation).  
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Perinatal Risk Factors: Implications for Preventive Studies 
Many of the factors and co-morbidities associated with CPIP can be used to identify populations 
at highest risk. Antenatal factors such as intrauterine growth restriction (IUGR), maternal hypertension, 
maternal smoking, and male gender are now appreciated to be key risk factors and highly predictive of 
chronic respiratory morbidity (24, 28). Postnatal events that increase the risk of BPD include severe 
respiratory failure, air leak, early pulmonary hypertension, systemic and pulmonary infections and the 
prolonged presence of a patent ductus arteriosus.  
Intrauterine Growth Restriction: One of the strongest factors reflecting the impact of fetal events 
in the pathogenesis of BPD is the presence of IUGR (29, 30). In one large study of preterm infants < 28 
weeks gestation, birth weight z-scores indicative of IUGR were more strongly linked with increased risk 
for BPD than numerous other prenatal, placental and postnatal factors (29). Furthermore, IUGR is an 
independent risk factor for late respiratory morbidities and abnormal lung function at school age (e.g. 
abnormal airway function, decreased lung surface area) (31, 32). 
 Placental abnormalities: Hypertensive disorders of pregnancy such as pre-eclampsia have been 
strongly associated with the development of BPD after preterm birth, even after accounting for IUGR (33). 
Experimental models that alter placental function and structure to create severe IUGR impair fetal lung 
airspace and vascular growth in the late gestation fetus, which may persist throughout postnatal life (34). 
In preterm infants with IUGR, histologic placental abnormalities of “maternal under-perfusion” are 
strongly linked with BPD and BPD-associated pulmonary hypertension. Cord blood biomarkers for 
assessing BPD risk may include circulating fetal proteins such as vascular endothelial growth factor 
(VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1; also known as soluble VEGF receptor-1) (35).  
 Maternal smoking: Maternal smoking is a known risk factor for impaired lung function, wheezing 
and asthma in children at 4 – 12 years of age (28, 36) and likely contributes to CPIP outcomes (24, 37). 
Possible mechanisms underlying the harmful effects of maternal smoking on fetal lung development 
could be dysregulated cytokine production and oxidative stress, or direct effects of nicotine on lung 
receptors resulting in altered lung development and impaired lung function at birth (38). More recent 
research has suggested an interaction of in utero and early life smoke exposure with upregulation of 
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asthma susceptibility genes (39) and new evidence suggests the effects of maternal smoking can be 
modified by agents such as Vitamin C (40). 
 Inflammation and infection: Preterm birth is frequently associated with fetal exposure to 
inflammation/infection as diagnosed by histopathology (e.g. chorioamnionitis, funisitis), culture, or 
increased concentrations of pro-inflammatory cytokines in amniotic fluid or cord blood (41). 
Chorioamnionitis rarely results in invasive infection, but indicators of lung inflammation prior to birth are 
frequently found (42). These antenatal exposures are associated with lung abnormalities that range from 
severe diffuse pneumonia (indistinguishable from severe RDS) to mature lungs for gestational age with 
lower risk for BPD. Although fetal modulations of immune and inflammatory responses can contribute to 
postnatal lung injury and the development of BPD, the exact mechanisms are poorly understood (43). 
Postnatally, lung inflammation can be triggered by exposure to systemic infection, high O2 
concentrations, positive pressure ventilation, and/or a patent ductus arteriosus. Increased concentrations 
of inflammatory mediators could contribute to bronchoconstriction, vasoconstriction and increased 
vascular permeability characteristic of the lungs of these infants and might also be responsible for the 
decreased alveolarization seen in infants dying with BPD (44). 
 Pulmonary vascular disease: Disruption of pulmonary angiogenesis due to antenatal factors such 
as chorioamnionitis, pre-eclampsia, maternal smoking, and postnatal injury can cause pulmonary vascular 
disease that leads to pulmonary hypertension (PH) and impaired distal lung growth (19). 
Echocardiographic findings of pulmonary vascular disease shortly after preterm birth are strongly 
associated with the development and severity of BPD and PH at 36 weeks PMA, as well as late 
respiratory complications including respiratory exacerbations, hospitalizations and the need for asthma 
medications (45). Echocardiographic evidence of early PH may be an excellent predictor of severe BPD 
and an early predictive biomarker for enrolling the highest risk infants into clinical intervention trials. 
 Early respiratory failure: Severe RDS and the need for high inspired O2 concentrations and 
prolonged ventilatory support are clearly associated with an increased incidence of BPD. The ongoing 
need for respiratory support at day seven improves the predictive accuracy for BPD, with rates 
approaching 65% (27, 46, 47). O2 targeting trials have shown increased pulmonary morbidity in infants 
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maintained within higher O2 target ranges, suggesting that higher inspired O2 may produce worse 
pulmonary outcomes. A recent secondary analysis of the TOLSURF trial showed a strong association 
between cumulative O2 exposure during the first 14 days and a higher incidence of BPD at 36 weeks 
PMA (48). Thus, an analysis of cumulative inspired O2 concentrations (area under the curve) may permit 
the early prediction of BPD or other forms of CPIP with a high degree of specificity and sensitivity (48).  
 
Research agenda 
The research agenda for drug development needs to sharpen its focus on rigorous data collection 
combined with a mechanistic approach appropriate for clinical scientists.  
 
1. Identification of subgroups of CPIP: Rigorous studies are needed to determine that specific risk 
subgroups exist and can be reliably identified. Hypotheses about subgroups can be generated from 
epidemiological data (including cohorts that are characterized with modern methods, such as –omics) or 
from mechanistic data (usually derived from in vitro or animal models). One set of hypotheses could be 
based on the risk factors described above: for example, IUGR could be associated with different pathways 
and manifestations of CPIP when compared to perinatal inflammation. These studies should pay attention 
to genetic factors that may contribute to severe CPIP. Subgroups could be defined according to a priori 
criteria, or could be identified from linking clinically important outcomes to phenotypic or –omic profiles. 
Proposed subgroups need to be confirmed using validation cohorts.  Biomarker inquiries should cover the 
pre-analytic and analytic characterization of proposed biomarkers and quantification of the variability of 
that biomarker observed in the target population. 
2. Identification of respiratory outcomes: Specific respiratory outcomes at the proposed time 
points need to be reliably ascertained as clinically relevant or have strong associations with functionally 
relevant outcomes. International data sets and registries should be used to determine covariates that 
contribute to the progression or resolution of chronic pulmonary insufficiency. New techniques should be 
developed and studied to better standardize pulmonary assessment, such as imaging techniques that 
measure alveolar numbers and sizes (26), or noninvasive measurements of exhaled gases.    
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3. Relationship between subgroups and outcomes: Studies need to determine whether specific subgroups 
are strongly associated with clinically significant outcomes. Newer methodologies such as phenotype-
wide association study (PheWAS), structural equation modeling, or latent variable analysis should be 
considered. Characterization needs to include quantification of the variation in the strength of the 
association within and across clinical settings, as well as an estimate of the magnitude of the association. 
4. Impact of a drug or other intervention on an outcome among specific subgroups: This involves testing 
whether members of a subgroup are more likely to have a beneficial outcome, or less likely to have an 
adverse outcome, in response to a drug across its therapeutic range.  
We suggest that these investigations will require a staged program linking subgroup 
characterization to outcomes and drug response. The stages could be done in parallel in carefully designed 
studies. The use of BPD as an outcome for drug development in the absence of these steps may be a 
historic necessity but it has led to a lack of clarity and may have led to inappropriate rejection of 
promising drugs. Future work will benefit from the steps we outline. 
 
Conclusions 
A single definition of CPIP is unlikely to address all the needs of trialists, drug developers, 
parents and regulators for meaningful and valid endpoints. For some purposes, refining the existing 36-
week PMA definition of BPD to better predict long-term pulmonary insufficiency would retain the 
advantages of assigning a diagnosis prior to discharge. There is also a need to better understand the 
impact of severe lung disease that leads to early mortality prior to the designation of BPD at 36 weeks; 
this has been an overlooked population that needs study and warrants clinical trial work. A 40-week PMA 
definition would be anticipated to reduce the 'noise' by eliminating infants with minimal disease, but 
would need further validation for its predictive value. A one-year CGA outcome capturing features of 
chronic respiratory morbidity remains essential to regulators and families as a clinical meaningful 
outcome, but needs validation, comprehensive follow-up and the ability to control for post-discharge 
environmental factors. Finally, identification of subpopulations of infants at highest risk, or with 
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pathophysiology that may benefit from a particular therapy, is needed to allow clinical trials to function 
optimally and conclude with clear answers. 
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